New Version of the Q&A Catalogue published
![Drug Master File Procedures in the EU, the US and Japan - Live Online Training](files/eca/userImages/training.img/Z-ECA-Drug-Master-File-Procedures-LOT.jpg)
Recommendation
17/18 September 2024
With updates on the CEP 2.0!
Again, the question and answer catalogue "QUESTIONS AND ANSWERS ON REGULATORY EXPECTATIONS FOR MEDICINAL PRODUCTS FOR HUMAN USE DURING THE COVID-19 PANDEMIC" of the Heads of Medicines Agencies (HMA), European Medicines Agency (EMA) and the European Commission (EC) has been extended and updated. This third version additionally lists points 4.2-4.4 and includes an update of point 2.2.
The question and answer catalogue provides instructions on the current handling of marketing authorisation procedures and existing marketing authorisations and informs about the handling of variation procedures or marketing authorisation renewals. Additional guidance and practical approaches to these issues can be found in the "Practical guidance of the CMDh for facilitating the handling of processes during the COVID-19 crisis".
Here, you will find the latest version of the "QUESTIONS AND ANSWERS ON REGULATORY EXPECTATIONS FOR MEDICINAL PRODUCTS FOR HUMAN USE DURING THE COVID-19 PANDEMIC" and the corresponding explanations of "Practical guidance of the CMDh for facilitating the handling of processes during the COVID-19 crisis".
Related GMP News
17.07.2024EMA: Q&A document for "Centralised Procedures" updated again
16.07.2024CMDh/HMA: New Update of the Q&A List on Variations
18.06.2024EDQM: New Guideline for sterile Substances published for Comment
18.06.2024EMA updates IRIS Guide
02.05.2024EDQM: Updated Information on the Quality Overall Summary (Module 2)
02.05.2024EDQM: Manufacturing Sites in CEP 2.0?